spironolactone and ACEI or ARBs - safety advice
Last reviewed 01/2018
Reminder for healthcare professionals:
- concomitant use of spironolactone with ACEi or ARB is not routinely recommended
because of the risks of severe hyperkalaemia, particularly in patients with
marked renal impairment
- use the lowest effective doses of spironolactone and ACEi or ARB if coadministration
is considered essential
- regularly monitor serum potassium levels and renal function
- interrupt or discontinue treatment in the event of hyperkalaemia
Reference:
- Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update February 2016.